Kymera Therapeutics to Participate in Fireside Chat at the BofA Securities 2025 Health Care Conference

Core Insights - Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing oral small molecule degrader medicines for immunological diseases [1][3] - The company will participate in a fireside chat at the BofA Securities 2025 Healthcare Conference on May 14, 2025 [1] - A live webcast of the presentation will be available on the company's website, with a replay archived post-event [2] Company Overview - Kymera Therapeutics is pioneering targeted protein degradation (TPD) to create medicines for critical health issues, aiming to improve patient outcomes significantly [3] - The company has advanced its first degrader into clinical trials for immunological diseases and is building a robust pipeline of oral small molecule degraders [3] - Founded in 2016, Kymera has been recognized as one of Boston's top workplaces in recent years [3] Communication and Information Availability - Kymera encourages investors and the public to review information posted on its website and social media platforms, which may contain material information [4] - The company utilizes its website for corporate disclosures, investor presentations, SEC filings, and press releases [4]